日本語 
PRISM BioLab and Receptor.AI have signed a collaboration agreement to work together on drug discovery. The goal is to combine their technologies and build a platform that can identify new small molecule therapies which traditional drug discovery methods cannot detect.
PRISM brings its PepMetics chemistry to the partnership. These are small molecules designed to mimic specific protein structures such as alpha helix and beta turn motifs. The idea is to create compounds that can interact with difficult biological targets like intracellular protein protein interactions, membrane proteins, and complex receptor systems.
Receptor.AI contributes its AI based molecular design system. The platform uses physics informed models and multi objective algorithms to guide how potential drug molecules are designed and optimized. By combining PRISM’s chemical library with Receptor.AI’s design engine, the two companies plan to generate new hit and lead compounds that could eventually move toward clinical development.
Also Read: Fujitsu and DT-Axis Partnership Signals a New Phase for Digital Health in Japan
The collaboration will begin with a single receptor target linked to metabolic disease, including obesity. Receptor.AI will focus on designing candidate molecules while both companies also explore partnerships with pharmaceutical firms interested in using the combined platform.
Beyond developing potential therapies, the companies also want to build technical know-how around this integrated approach. That knowledge could then support future collaborations and expand the use of AI guided drug discovery in more therapeutic areas.
English